Nascent Biotech Inc.: Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

VERO BEACH, FL / ACCESSWIRE / September 13, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development

Related Keywords

Sean Carrick ,Exchange Commission ,Company Phase ,Nascent Biotech Inc ,Securities Exchange ,Nascent Biotech Inc Form ,Nascent Biotech ,Fourth Cohort ,Brain Cancer ,Fifth Cohort ,Securities Act ,Securities Exchange Act ,Private Litigation Reform Act ,Nascent ,Biotech ,Ompletes ,Fourth ,Cohort ,Hase ,Human ,Trial ,Primary ,Metastatic ,Rain ,Dancer ,